Drug Discovery

Teva, Modag to develop drug candidates for neurodegenerative disease

Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter's drug candidates, anle138b and sery433, for neurodegenerative disease.

Vertex, Mammoth partner to develop in vivo gene-editing therapies

Vertex Pharmaceuticals has collaborated with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases.

EMA’s CHMP begins rolling review of molnupiravir to treat Covid-19 in adults

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a rolling review of molnupiravir (MK-4482 and EIDD-2801), an investigational oral antiviral medicine, to treat adult patients with Covid-19.

Atreca, Gates MRI partner to develop antibody for malaria prevention

Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.

Amgen completes acquisition of biotechnology firm Teneobio

Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn.

Silence Therapeutics, Hansoh partner to develop novel siRNA therapeutics

Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform.

Exelixis, STORM partner to develop novel drug leads to treat cancer

Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes.

Intellia Therapeutics and SparingVision enter strategic collaboration to develop ocular therapies

Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases.

US FDA and EMA accept application for Novartis’ Beovu to treat DME

The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu (brolucizumab) to treat patients with diabetic macular edema (DME).